7 results about "Protein link" patented technology

A conditionally active bispecific antibody comprising: an IgG antibody or antibody fragment that binds to human EpCAM protein, the IgG antibody or antibody fragment comprising a light chain variable region having three complementarity-determining regions L1, L2, and L3, and a heavy chain variable region having three complementarity-determining regions H1, H2, and H3; and at least one scFv antibody fragment that binds to a T lymphocyte protein linked to the C-terminus of at least one light chain of the IgG antibody or antibody fragment.

The present disclosure is directed to compositions comprising mitochondrial optogenetics-based gene therapies and their methods of use. In some embodiments, a composition described herein comprises an expression vector comprising a first nucleic acid sequence encoding a channelrhodopsin fusion protein and a second nucleic acid sequence encoding a luciferase protein. In some cases, the first nucleic acid sequence and the second nucleic acid sequence are operably linked to an expression control sequence. In some instances, the channelrhodopsin fusion protein comprises a channelrhodopsin protein linked to an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS). In some implementations, when the expression vector is expressed, the luciferase protein is localized to the cytosol. In some cases, the IMM-MLS comprises a leading sequence from a mitochondrial inner membrane protein selected from ABCB10, ABCB140, Cytochrome C, and renal outer medullary potassium channel (ROMK).

This invention provides a material for detecting serum plasma anti-nicotinic acetylcholine receptor antibodies and its method of use. The material comprises HEK293T cells transfected with three recombinant expression plasmids: the first plasmid encodes a truncated AChR α subunit; the second plasmid is a polycistronic plasmid encoding a fusion protein composed of a truncated AChR β subunit, an AChR δ subunit, and rapsyn protein linked by a P2A peptide; and the third plasmid encodes a truncated AChR γ subunit or ε subunit. After co-transfection with PEI, the cells are cultured in fresh complete medium for 25-35 hours after 7-9 hours post-transfection, followed by fixation, blocking, and preservation. This invention, through a three-plasmid system and antigen truncation modification, reduces cytotoxicity while ensuring high expression of the functional pentamer, significantly improving detection sensitivity and reagent shelf life.

Provided herein are compositions and methods for the production of heterologous proteins in a cell including axonemes. The cells include a nucleic acid encoding a fusion protein expressed in the axoneme. The fusion protein includes an axonemal protein linked to a heterologous protein, and the fusion protein provides axonemal function to the cell.

Method and kit for elimination of rheumatoid factor interference in immunoassays The invention relates to an in vitro method of reducing and / or eliminating unwanted detection of an IgG antibody in an immunoassay on a biological sample containing rheumatoid factor (RF), the method comprising contacting said biological sample with a RF interference-reducing protein comprising an amino acid sequence of SEQ ID NO. 1, 2 or 3, and capable of binding to the Fc domain of IgG antibodies. Also disclosed is an in vitro method for detecting antibodies specific to an antigen in a biological sample that belong to one or more immunoglobulin classes other than IgG, which makes use of the aforementioned RF interference-reducing protein. There are further described a kit for carrying out the method of the invention and the use in said method of a fusion protein comprising said RF interference-reducing protein linked to a fusion partner.

The present invention provides a conditionally active bispecific antibody comprising: an IgG antibody or antibody fragment binding to a human EpCAM protein, comprising a light chain variable region having three complementarity determining regions L1, L2 and L3 and a heavy chain variable region having three complementarity determining regions H1, H2 and H3; and at least one scFv antibody fragment binding to a T-lymphocyte protein attached to the C-terminus of at least one light chain of the IgG antibody or antibody fragment.

We provide peptide linkers and multi-domain proteins. [Solution] A peptide linker is provided, comprising y consecutive residues selected from the group consisting of Gly and Ser, wherein y = 5-100, 5-70, 5-60, 5-50 or 10-100, 10-70, 10-60 or 10-50, and the last serine is at position y-2 or y-3. The use of the peptide linker for joining the first and second domains of a multidomain protein is also provided. A multidomain protein linked by the peptide linker is also provided, preferably the multidomain protein is a bispecific antibody.